Welcome to our dedicated page for Quantum-Si news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si stock.
Quantum-Si Incorporated develops proteomics technology for single-molecule protein sequencing and protein analysis. Its updates center on benchtop platform development, real-time kinetic-based detection, and product work around Proteus instruments, the KinetIQ Array and Platinum Pro customer use.
Recurring company news includes quarterly financial results and non-GAAP operating measures, Proteus prototype and integrated-instrument sequencing milestones, amino-acid detection coverage, customer sample testing, scientific posters and manuscripts using Quantum-Si technology, investor conference participation, and equity-inducement grants under Nasdaq rules.
Quantum-Si Incorporated (Nasdaq: QSI) has successfully completed its business combination with HighCape Capital Acquisition Corp. (Nasdaq: CAPA), resulting in over $500 million for the development of its semiconductor chip-based protein sequencing technology. The combined company, now trading as Quantum-Si, aims to disrupt the $21 billion academic research and drug discovery market with its unique end-to-end solution. The company’s leadership includes experienced executives and it anticipates launching its products commercially in 2022.